You are here: Industry Insights > Venetoclax

News List

The New Indication of Venetoclax, a Popular Drug of AbbVie, Declared in China Dupeipei/PharmaSources
July 03, 2023
On June 21, Class 5.1 import application for 「Venetoclax tablet」 submitted by AbbVie was accepted by the CDE.
NICE recommend venetoclax and azacytidine for patients with aggressive blood cancer PharmaTimes
December 17, 2021
Venetoclax is an oral once-daily treatment, which blocks the action of the B-cell lymphoma-2 protein, the presence of which helps cancer cells survive.
Imbruvica®-based regimens induce lasting remissions in leukaemia trials europeanpharmaceuticalreview
May 21, 2021
Imbruvica® (ibrutinib) plus ventoclax and single-agent Imbruvica induced remissions lasting up to seven years in first-line treatment of chronic lymphocytic leukaemia.
Actinium Completes Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial americanpharmaceuticalreview
April 02, 2021
Actinium Pharmaceuticals announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia ...
Two medicines accepted for use by NHS Scotland pharmatimes
December 09, 2020
The Scottish Medicines Consortium has approved NHS funding for treatments for blood cancer and a rare muscle disorder.
NICE recommends new chemo-free chronic lymphocytic leukaemia treatment europeanpharmaceuticalreview
November 16, 2020
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.
Positive results announced for acute myeloid leukaemia treatment trial europeanpharmaceuticalreview
March 27, 2020
Positive topline results have been announced from a Phase II trial of VENCLEXTA® (venetoclax) in combination with azacitidine in patients with acute myeloid leukaemia (AML).
VENCLEXTA, Low-Dose Cytarabine Combination Study for AML Does Not Meet Primary Endpoint americanpharmaceuticalreview
March 04, 2020
AbbVie announced the VIALE-C (M16-043) trial of venetoclax (VENCLEXTA®) in combination with low-dose cytarabine (LDAC) versus LDAC in combination with placebo did not meet its primary endpoint of ...
Curis Announces Positive Data in Ongoing Study of Fimepinostat, Venetoclax Combo americanpharmaceuticalreview
December 12, 2019
Curis announced preliminary tolerability and PK data from its ongoing Phase 1 dose-finding study of fimepinostat, a small molecule dual inhibitor of PI3K/HDAC and suppressor of MYC ...
Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in AML americanpharmaceuticalreview
December 11, 2019
Trovagene announced new in-vitro and in-vivo data suggesting that onvansertib may provide a new therapeutic option for patients who develop resistance to frontline treatment with venetoclax.

Previous page 1 2 Next page